HilleVax's Phase 2b NEST-IN1 Study of Norovirus Vaccine Fails to Meet Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
HilleVax, Inc. (NASDAQ:HLVX) announced that its Phase 2b NEST-IN1 study of the norovirus vaccine HIL-214 in infants did not meet its primary efficacy endpoint. The study showed a vaccine efficacy of 5%, with no clinical benefit observed across secondary endpoints. HilleVax plans to discontinue further development of HIL-214 in infants but will explore its potential in adults.
July 08, 2024 | 11:35 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HilleVax's Phase 2b NEST-IN1 study of the norovirus vaccine HIL-214 in infants failed to meet its primary efficacy endpoint, showing only 5% efficacy. The company will discontinue development in infants but will explore potential in adults.
The failure to meet the primary endpoint in a significant clinical trial is likely to negatively impact HilleVax's stock price in the short term. The decision to discontinue development in infants further underscores the setback, although the exploration of potential in adults may offer some future hope.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100